{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:54:33Z","timestamp":1781859273891,"version":"3.54.5"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["23ZR1474900"],"award-info":[{"award-number":["23ZR1474900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["24ZR1413700"],"award-info":[{"award-number":["24ZR1413700"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["SYS202205"],"award-info":[{"award-number":["SYS202205"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2024CXPT029"],"award-info":[{"award-number":["2024CXPT029"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2021ZD0203500"],"award-info":[{"award-number":["2021ZD0203500"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571743"],"award-info":[{"award-number":["82571743"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bbrc.2026.153411","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:07:56Z","timestamp":1770311276000},"page":"153411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SLL-023ACP, a KOR\/MOR dual agonist, produces potent antinociception with fewer side effects"],"prefix":"10.1016","volume":"806","author":[{"given":"Yi-Quan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Gao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Wen","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Gen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-5325","authenticated-orcid":false,"given":"Yu-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbrc.2026.153411_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0031-6997(25)06958-3","article-title":"International union of pharmacology. XII. Classification of opioid receptors","volume":"48","author":"Dhawan","year":"1996","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbrc.2026.153411_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117865","article-title":"PET imaging of the opioid system using radioligands: synthetic approaches and translational applications","volume":"296","author":"Reale","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bbrc.2026.153411_bib3","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.3390\/ijms20174302","article-title":"The mechanisms involved in morphine addiction: an overview","volume":"20","author":"Listos","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bbrc.2026.153411_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpainsymman.2025.02.020","article-title":"Harms of morphine for chronic breathlessness in relation to dose, duration and titration phase","volume":"69","author":"Ekstr\u00f6m","year":"2025","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.bbrc.2026.153411_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102704","article-title":"Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: a systematic review and meta-analysis","volume":"125","author":"Kistemaker","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2026.153411_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2025.105998","article-title":"A multiscale atlas of Oprm1-expressing neurons in the central nervous system: brain-wide distribution, circuit functions, and translational therapeutic implications","volume":"188","author":"Zhang","year":"2025","journal-title":"Neurochem. Int."},{"issue":"6","key":"10.1016\/j.bbrc.2026.153411_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bja.2019.03.006","article-title":"Hot topics in opioid pharmacology: mixed and biased opioids","volume":"122","author":"Azzam","year":"2019","journal-title":"Br. J. Anaesth."},{"issue":"20","key":"10.1016\/j.bbrc.2026.153411_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bmcl.2015.07.064","article-title":"Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives","volume":"25","author":"Deekonda","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"10","key":"10.1016\/j.bbrc.2026.153411_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/acs.jmedchem.6b00308","article-title":"Effects of N-Substitutions on the tetrahydroquinoline (THQ) core of mixed-efficacy \u03bc-Opioid receptor (MOR)\/\u03b4-Opioid receptor (DOR) ligands","volume":"59","author":"Harland","year":"2016","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bbrc.2026.153411_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/acs.jmedchem.5b01270","article-title":"Further optimization and evaluation of bioavailable, Mixed-Efficacy \u03bc-Opioid Receptor (MOR) Agonists\/\u03b4-Opioid receptor (DOR) antagonists: balancing MOR and DOR affinities","volume":"58","author":"Harland","year":"2015","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bbrc.2026.153411_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40263-022-00924-2","article-title":"Current and future therapeutic options in pain management: Multi-mechanistic opioids involving both MOR and NOP receptor activation","volume":"36","author":"Coluzzi","year":"2022","journal-title":"CNS Drugs"},{"issue":"21","key":"10.1016\/j.bbrc.2026.153411_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acs.jmedchem.5b01170","article-title":"Discovery of novel multifunctional ligands with \u03bc\/\u03b4 opioid Agonist\/Neurokinin-1 (NK1) antagonist activities for the treatment of pain","volume":"58","author":"Giri","year":"2015","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbrc.2026.153411_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1213\/ANE.0000000000006266","article-title":"OCP002, a mixed agonist of opioid and cannabinoid receptors, produces potent antinociception with minimized side effects","volume":"136","author":"Xu","year":"2023","journal-title":"Anesth. Analg."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153411_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/AAP.0000000000000326","article-title":"Effects of intrathecal \u03ba-Opioid receptor agonist on morphine-induced itch and antinociception in mice","volume":"41","author":"Sakakihara","year":"2016","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.bbrc.2026.153411_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2025.174056","article-title":"KOR agonists for the treatment and\/or prevention of opioid use disorder and cocaine use disorder","volume":"254","author":"Liu-Chen","year":"2025","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"19","key":"10.1016\/j.bbrc.2026.153411_bib16","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/acschemneuro.0c00407","article-title":"Comparison of pharmacological properties between the Kappa Opioid receptor agonist nalfurafine and 42B, its 3-Dehydroxy analogue: disconnect between in vitro agonist bias and in vivo pharmacological effects","volume":"11","author":"Cao","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbrc.2026.153411_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.964724","article-title":"Signaling underlying kappa opioid receptor-mediated behaviors in rodents","volume":"16","author":"Liu-Chen","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbrc.2026.153411_bib18","article-title":"Agonist-Promoted phosphorylation and internalization of the Kappa opioid receptor in mouse brains: lack of connection with conditioned place aversion","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153411_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/164_2020_400","article-title":"Clinical profiles of nalfurafine hydrochloride for the treatment of pruritus patients","volume":"271","author":"Miyamoto","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153411_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2021_443","article-title":"Preclinical studies on Nalfurafine (TRK-820), a clinically used KOR agonist","volume":"271","author":"Zhou","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbrc.2026.153411_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0165-6147(98)01169-9","article-title":"mu-Opposing actions of the kappa-opioid receptor","volume":"19","author":"Pan","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.bbrc.2026.153411_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.bbrc.2026.153411_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates Analgesia by the Mu opioid receptor-targeting agonist morphine","volume":"371","author":"Kaski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.bbrc.2026.153411_bib24","doi-asserted-by":"crossref","first-page":"7074","DOI":"10.1038\/s41467-025-62382-w","article-title":"Neuropeptide Y neurons mediate opioid-induced itch by disinhibiting GRP-GRPR microcircuits in the spinal cord","volume":"16","author":"Zeng","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbrc.2026.153411_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00192549","article-title":"The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist","volume":"46","author":"Rimoy","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153411_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113524","article-title":"Effects of processed Aconiti tuber on the extinction and reinstatement of morphine-induced conditioned place preference in rats","volume":"267","author":"Wu","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bbrc.2026.153411_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108244","article-title":"Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL\/6J mice","volume":"176","author":"Zhang","year":"2020","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.bbrc.2026.153411_bib28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","article-title":"Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys","volume":"237","author":"Zamarripa","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbrc.2026.153411_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/164_2020_420","article-title":"Antipruritic effects of Kappa opioid receptor agonists: evidence from rodents to humans","volume":"271","author":"Inan","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"issue":"22","key":"10.1016\/j.bbrc.2026.153411_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/jm4012214","article-title":"Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu\/kappa opioid receptor dual selectivity","volume":"56","author":"Yuan","year":"2013","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bbrc.2026.153411_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/jm301543e","article-title":"Orvinols with mixed kappa\/mu opioid receptor agonist activity","volume":"56","author":"Greedy","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153411_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1124\/jpet.123.001870","article-title":"NCP, a dual Kappa and Mu opioid receptor agonist, is a potent analgesic against inflammatory pain without reinforcing or aversive properties","volume":"389","author":"Huang","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbrc.2026.153411_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117449","article-title":"Structure-activity relationship analysis of meta-substituted N-cyclopropylmethyl-nornepenthones with mixed KOR\/MOR activities","volume":"289","author":"Tang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bbrc.2026.153411_bib34","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1021\/acs.jmedchem.3c02439","article-title":"Discovery of an ortho-substituted N-Cyclopropylmethyl-7\u03b1-phenyl-6,14-endoethano-tetrahydronorthebaine derivative as a selective and Potent Kappa Opioid receptor agonist with subsided sedative effect","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bbrc.2026.153411_bib35","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.1c01082","article-title":"Discovery of an M-Substituted N-Cyclopropylmethyl-7\u03b1-phenyl-6,14-endoethanotetrahydronorthebaine as a selective, potent, and orally active \u03ba-Opioid receptor agonist with an improved central nervous System safety profile","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bbrc.2026.153411_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/acschemneuro.6b00321","article-title":"The pharmacological heterogeneity of nepenthone analogs in conferring highly selective and potent \u03ba-Opioid agonistic activities","volume":"8","author":"Li","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"14","key":"10.1016\/j.bbrc.2026.153411_bib37","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1016\/j.bmc.2018.07.020","article-title":"7\u03b2-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues","volume":"26","author":"Sun","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"10.1016\/j.bbrc.2026.153411_bib38","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.9b00857","article-title":"Discovery of a highly selective and potent \u03ba opioid receptor agonist from N-Cyclopropylmethyl-7\u03b1-phenyl-6,14-endoethanotetrahydronortheba-ines with reduced Central Nervous System (CNS) side effects navigated by the message-address concept","volume":"62","author":"Xiao","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bbrc.2026.153411_bib39","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s41401-021-00761-x","article-title":"Novel selective \u03ba agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion","volume":"43","author":"Wei","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"12","key":"10.1016\/j.bbrc.2026.153411_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/aps.2010.164","article-title":"Effects of ATPM-ET, a novel \u03ba agonist with partial \u03bc activity, on physical dependence and behavior sensitization in mice","volume":"31","author":"Sun","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153411_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1124\/jpet.108.142802","volume":"329","author":"Wang","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.bbrc.2026.153411_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13104-020-04994-7","article-title":"Highly-selective \u03bc-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model","volume":"13","author":"Bartlett","year":"2020","journal-title":"BMC Res. Notes"},{"issue":"3","key":"10.1016\/j.bbrc.2026.153411_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.106.116780","article-title":"Pharmacological characterization of the nociceptin\/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies","volume":"321","author":"Rizzi","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.bbrc.2026.153411_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/aps.2014.120","article-title":"Novel \u03ba-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation","volume":"36","author":"Zhang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2026.153411_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2014.06.045","article-title":"Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET, an N-ethyl substituted aminothiazolomorphinan with \u03ba agonist and \u03bc agonist\/antagonist activity","volume":"740","author":"Sun","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153411_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbrc.2022.04.083","article-title":"Antinociceptive activities and mechanism of action of Cepharanthine","volume":"614","author":"Wei","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2-3","key":"10.1016\/j.bbrc.2026.153411_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejphar.2008.02.028","article-title":"LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential","volume":"584","author":"Tao","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbrc.2026.153411_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1476-5381.1980.tb07041.x","article-title":"A classification of opiate receptors that mediate antinociception in animals","volume":"69","author":"Tyers","year":"1980","journal-title":"Br. J. Pharmacol."},{"issue":"16","key":"10.1016\/j.bbrc.2026.153411_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0024-3205(99)00417-8","article-title":"Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist","volume":"65","author":"Endoh","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2026.153411_bib50","article-title":"Antinociceptive and antipruritic effects of HSK21542, a peripherally-restricted Kappa Opioid receptor agonist, in animal models of pain and itch","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbrc.2026.153411_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1124\/pr.111.004598","article-title":"Functional selectivity at the \u03bc-opioid receptor: implications for understanding opioid analgesia and tolerance","volume":"63","author":"Raehal","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.bbrc.2026.153411_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14728222.2019.1586882","article-title":"Current strategies toward safer mu opioid receptor drugs for pain management","volume":"23","author":"Ehrlich","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"issue":"625","key":"10.1016\/j.bbrc.2026.153411_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"issue":"12","key":"10.1016\/j.bbrc.2026.153411_bib54","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41386-025-02214-z","article-title":"Role of \u03b2-Arrestin 2 in the antinociceptive and side effect profile of morphine and the novel mu opioid receptor agonists, kurkinorin and kurkinol","volume":"50","author":"van de Wetering","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"18","key":"10.1016\/j.bbrc.2026.153411_bib55","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.3390\/molecules26185517","article-title":"Antipruritic effect of Nalbuphine, a Kappa opioid receptor agonist, in mice: a pan antipruritic","volume":"26","author":"Inan","year":"2021","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.bbrc.2026.153411_bib56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1021\/jm061327z","article-title":"Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors","volume":"50","author":"Peng","year":"2007","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bbrc.2026.153411_bib57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bmcl.2009.02.078","article-title":"Syntheses of novel high affinity ligands for opioid receptors","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"3-4","key":"10.1016\/j.bbrc.2026.153411_bib58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0376-8716(85)90066-3","article-title":"Nalbuphine","volume":"14","author":"Schmidt","year":"1985","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.bbrc.2026.153411_bib59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2006.01.013","article-title":"Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats","volume":"84","author":"Tao","year":"2006","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.bbrc.2026.153411_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF03006882","article-title":"Comparison of the calming and sedative effects of nalbuphine and pentazocine for paediatric premedication","volume":"27","author":"Rita","year":"1980","journal-title":"Can. Anaesth. Soc. J."},{"issue":"3","key":"10.1016\/j.bbrc.2026.153411_bib61","first-page":"6","article-title":"The use of nalbuphine in paediatric anaesthesia","volume":"47","author":"Kubica-Cieli\u0144ska","year":"2015","journal-title":"Anaesthesiol. Intensive Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153411_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0952-8180(93)90081-O","article-title":"The effect of nalbuphine and droperidol on spontaneous movements during induction of anesthesia with propofol in children","volume":"5","author":"Borgeat","year":"1993","journal-title":"J. Clin. Anesth."},{"key":"10.1016\/j.bbrc.2026.153411_bib63","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3727\/107156999819565766","article-title":"Comparison of antinociceptive effects induced by Kappa opioid agonists in Male and female mice","volume":"4","author":"Patrick","year":"1999","journal-title":"Analgesia"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26001750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:20:51Z","timestamp":1781857251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26001750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"alternative-id":["S0006291X26001750"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153411","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SLL-023ACP, a KOR\/MOR dual agonist, produces potent antinociception with fewer side effects","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153411"}}